Sartorius AG

EANS-Adhoc: Sartorius AG
Order intake and sales revenue substantially increased for both divisions | Positive earnings contributed by the Mechatronics Division | Group operating earnings jumped nearly 50% | Expectations for 2010 confirmed

-------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Figures for the First Half of 2010 23.07.2010 In the first half of 2010, order intake for the Sartorius Group climbed 9.8% (currency-adjusted: +8.4%) from EUR306.4 million to EUR336.4 million. Sales revenue rose 6.3% (currency-adj.: +5.1%) to EUR315.2 million from EUR296.5 million a year ago. The Biotechnology Division received orders valued at EUR221.4 million, up from EUR203.5 million in the previous year, a plus of 8.8% (currency-adj.: +7.4%), and increased its sales revenue 5.7% (currency-adj.: +4.6%) to EUR209.1 from EUR197.8 million a year earlier. The Mechatronics Division posted a significant gain in order intake of 11.8% (currency-adj.: +10.4%) to EUR115.1 million from EUR102.9 million in the previous year; its sales revenue grew 7.5% (currency-adj.: +6.1%) to EUR106.1 million, up from EUR98.7 million a year ago. Consolidated earnings before interest, taxes and amortization and adjusted for extraordinary expenses of EUR1.9 million (prev. year: EUR16.3 mn) — underlying EBITA — surged 47.0% to EUR36.3 million, up from EUR24.7 million a year earlier; the respective margin rose from 8.3% to 11.5%. The Biotechnology Division contributed an underlying EBITA of EUR31.5 million, up from EUR28.0 million a year ago, which means its margin increased from 14.2% to 15.0%. After posting a loss of EUR3.4 million in the year-earlier period, the Mechatronics Division contributed a positive result to Group earnings, reporting an underlying EBITA of EUR4.8 million and improving its profit margin from -3.4% to 4.5%. Excluding non-cash amortization, underlying net profit after minority interest for the first half totals EUR15.9 million (prev. year: EUR6.4 mn); the respective earnings per share are at EUR0.93, up from EUR0.37 a year ago. The results achieved meet our expectations for both divisions and confirm our outlook for the current fiscal year. This outlook forecasts sales growth of slightly above 5% in constant currencies and further improvement of the operating EBITA margin by one to two percentage points as well as a significantly positive operating cash flow. Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, will discuss the results with analysts and investors on Monday, July 26, at 4:00 p.m. Central European Time in a webcast teleconference. You may dial into the teleconference starting at 3:45 p.m. CET at the following numbers: Germany +49 (0)69 2222 2245; France +33 (0)1 70 99 42 73; UK +44 (0)20 7138 0824; USA +1 212 444 0481 The dial-in code is as follows: 4383672 The webcast and presentation can be viewed at www.sartorius.com. end of announcement euro adhoc -------------------------------------------------------------------------------- ots Originaltext: Sartorius AG Im Internet recherchierbar: http://www.presseportal.ch Further inquiry note: Andreas Wiederhold Team Leader Treasury & Investor Relations Telefon: +49 (0)551 308-1668 E-Mail: andreas.wiederhold@sartorius.com Branche: Biotechnology ISIN: DE0007165607 WKN: 716560 Index: CDAX, Prime All Share, Technology All Share Börsen: Frankfurt / regulated dealing/prime standard Berlin / free trade Hamburg / free trade Stuttgart / free trade Düsseldorf / free trade Hannover / free trade München / free trade

Das könnte Sie auch interessieren: